阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察

  目的  评价阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效及不良反应。  方法  回顾性分析2015年7月至2016年11月就诊于天津医科大学肿瘤医院，经病理学确诊为晚期三阴性乳腺癌，既往接受过两线以上化疗后疾病进展(progressive disease，PD)、服用阿帕替尼500 mg/d治疗的8例患者临床资料，所有患者均在接受2个周期以上治疗后评价疗效，观察PD时间、有效率、临床获益率及不良反应。  结果  8例患者共接受平均4个周期的治疗，经过中位随访时间为8 (4~11) 个月，其中部分缓解(partialremission，PR) 4例，疾病稳定(stable disease，SD) 3例，PD 1例；疾病控制率(disease control rate，DCR)为87.5%(7/8)，客观缓解率(objective response rate，ORR)为50% (4/8)，平均无进展生存期(progression free survival，PFS)为4.2个月。不良反应为手足综合征(3/8)、骨髓抑制(4/8)、高血压(2/8)、蛋白尿(3/8)、咯血(1/8)、恶心(2/8)、乏力(2/8) 等。  结论  阿帕替尼在三阴性乳腺癌的治疗中可获得一定的疗效及生存获益，且安全性好，不良反应可控。 

Clinical efficacy of apatinib in treating refractory triple-negative advanced breast cancer

Objective:To evaluate the effectiveness and safety of using apatinib in the treatment of refractory triple-negative advanced breast cancer. Methods:Eight cases of advanced triple-negative breast cancer patients confirmed via histopathology, who were previously treated with anthracycline, taxane, gemcitabine, capecitabine, and 500 mg/d apatinib in our hospital from July 2015 to November 2016, were retrospectively analyzed. The time of disease progress, effective rate, clinical benefits, and side effects were observed. Results:Eight patients were administrated with an average of 4 treatment cycles, and the effects were evaluated after 2 weeks. Four patients exhibited partial remission, 3 had a stable disease, and 1 had a progressive disease. The disease control rate was 87.5%, and the median progression free survival was 4.2 months. The main side effects were hand-foot syndrome (3/8), bone marrow arrest (4/8), hypertension (2/8), proteinuria (3/8), hemoptysis (1/8), nausea (2/8), and fatigue (2/8). Most of these side effects were tolerable. Conclusion:Apatinib can effectively and tolerably prolong survival time and improve the quality of life of patients with advanced triple-negative breast cancer.